Somatostatin Receptor Expression in the Thyroid Demonstrated with 111In-Octreotide Scintigraphy

W. Becker; U. Schrell; M. Buchfelder; J. Hensen; J. Wendler; M. Gramatzki; F. Wolf

doi:10.1055/s-0038-1629763

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1995; 34(03): 100-103
DOI: 10.1055/s-0038-1629763

Original Article

Schattauer GmbH

Somatostatin Receptor Expression in the Thyroid Demonstrated with ¹¹¹In-Octreotide Scintigraphy

W. Becker

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

U. Schrell

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

M. Buchfelder

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

J. Hensen

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

J. Wendler

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

M. Gramatzki

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

,

F. Wolf

¹From the Departments of Nuclear Medicine, Neurosurgery, Internal Medicine I and III, and the Institute of Clinical Rheumatology and Immunology of the University of Erlangen-Nuremberg, FRG

› Author Affiliations

Abstract

Summary

Neuroendocrine tumors with somatostatin receptor expression may be localized by ¹¹¹ln-octreotide scintigraphy. This study examines those thyroid conditions where ¹¹¹ ln-octreotide uptake could be observed also in the thyroid gland. 26 consecutive patients who underwent ¹¹¹ ln-octreotide scintigraphy for tumor localization were additionally examined for thyroid disease by sonography and ^99mTc-pertechnetate scintigraphy. 12 of these patients had no significant thyroid uptake and had an euthyroid normal-sized thyroid gland. 14 patiens with ¹¹¹ln thyroid uptakes had endemic goiters, two of them with thyroid autonomy and one with Graves’ disease. Thus, ¹¹¹ ln-octreotide thyroid uptake was predominantly seen in patients with endemic goiter with or without thyroid autonomy.

Zusammenfassung

Neuroendokrine Tumoren können szintigraphisch mit dem Somatostatinanalogon ¹¹¹ In-Octreotid lokalisiert werden. Diese Studie untersucht verschiedene Schilddrüsenerkrankungen, bei denen ebenfalls ein ¹¹¹ In-Octreotid-Uptake beobachtet werden konnte. 26 Patienten bei denen ein ¹¹¹ln-Octreotid-Szintigramm aufgenommen worden war, wurden zusätzlich einer eingehenden Schilddrüsendiagnostik mit Sonographie und quantitativ ausgewertetem Schilddrüsenszintigramm unterzogen. 12 dieser Patienten zeigten einen vernachlässigbaren ¹¹¹1n-Schild-drüsenuptake und hatten euthyreote und normal große Schilddrüsen. 14 Patienten mit einem erkennbaren ¹¹¹ln-Uptake hatten eine endemische Struma, davon 2 Patienten eine zusätzliche Schilddrüsenautonomie und eine Patientin eine floride Immunhyperthyreose.

Keywords

^1llln-octreotide - thyroid uptake - iodine deficiency

Schlüsselwörter

¹¹¹ln-Octreotid - Schilddrüsenuptake - Jodmangelstruma

Full Text

References

Literatur
1 Anonymous. Goitre and iodine deficiency in Europe. Report of the subcommittee of the study of endemic goitre and iodine deficiency of the European Thyroid Association. Lancet 1985; I: 1289-93.
2 Antonelli A, Lippi F, Gambuzza C, Neri S, Baschieri L. Somatostatin modulates thyroid function in toxic adenoma. J Endocrinol Invest 1992; 15 (Suppl 2): 123.
3 Bakker WH, Albert R, Bruns C. In-111-DTPA-D-PHE-octreotide. a potential radiopharmaceutical for imaging of somatostatin-receptor-positive tumors: synthesis, radiola-belling and in-vitro validation. Life Sci 1991; 49: 1583-91.
4 Bhathena SJ, Geraldine G, Rednian RS, Wahl L, Recant L. Identification of human mononuclear leukocyte-bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127.
5 Brunn J, Block U, Ruf G. et al. Volumetrie der Schilddrüsenlappen mittels Real-Time Sonographie. Dtsch Med Wschr 1981; 106: 1338-40.
6 Cadiout G, Lehy T, Bonifils S. Action of somatostatin analogue (SMS 201-995) on the growth-promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour. Eur J Clin Invest 1988; 18: 360.
7 Gärtner R, Bechtner G, Rafferzeder M. et al. Iodine regulation of the thyroid in vitro. In: Progress in endocrinology. Imura H. et al. (eds). Amsterdam: Elsevier; 1988: 1071-6.
8 Gärtner R, Greil W, Demharter R, Horn K. Involvement of cyclic AMP, iodide and metabolites of arachidonic acid in the regulation of the cell proliferation of isolated porcine thyroid follicles. Mol Cell Endocrinol 1985; 42: 145-55.
9 Grubeck-Lobenstein B, Buchan G, Sadeghi R. Transforming growth factor beta regulation of thyroid growth. Role in the pathogenesis of nontoxic goitre. J Clin Invest 1989; 83: 764-70.
10 Gutekunst R, Becker W, Hehrmann R, Ol-bricht T, Pfannenstiel P. Ultraschalldiagnostik der Schilddrüse. Dtsch Med Wschr 1988; 113: 1109-12.
11 Hierowski MT, Liebow C, du Sapin K, Schal-ly AV. Stimulation of somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. Febs Lett 1985; 179: 252.
12 Klijn JGM, Setyono-Han B, Bakker GH. Prophylactic neuropeptide-analog treatment of a transplantable pancreatic tumor in rats. Prog Cancer Res Ther 1988; 35: 350.
13 Krenning EP, Bakker HW, Kooig PPM. et al. Somatostatin-receptor scintigraphy with Indium-lll-DTPA-D-Phe-1 -Octreotide in man: metabolism, dosimetry and comparison with I-123-Tyr-3-Octreotide. J Nucl Med 1992; 33: 652-8.
14 Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 2: 450-82.
15 Lamberts SWJ, Reubi JC, Uiterlinden P. et al. Studies on the mechanism of action on the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the pro-lactin/adenocorticotropin-secreting pituitary tumor 7315a. Endocrinol 1986; 118: 2188.
16 Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86: 2003.
17 Maciel RMB, Moses AC, Villous G, Tramontane D, Ingbar SH. Demonstration of the physiological role of insulin-like growth-factor I in rat follicular cells in culture. J Clin Invest 1988; 82: 546-1553.
18 Mahlstedt J, Csirik J. TCTU – ein Progamm für das IMAC-System zur Durchführung des ^yymTc-Uptake-Tests in der Schilddrüsendiagnostik. Nuc Comp 1981; 12: 37-40.
19 Mascardo RN, Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinol 1988; 111: 1394.
20 Scicchitano R, Dazin P, Bienenstock J, Payan DG, Stanisz AM. Distribution of somatostatin receptors on murine spleen and Peyer’s patch T and B lymphocytes. Brain Behav Immunol 1987; 1: 173.
21 Siegel RA, Tolcsvai L, Rudin M. Partial inhibition of the growth of transplanted Dunning rat prostate tumors with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res 1988; 48: 4651.
22 Tramontano D, Moses AC, Picone R, Ingbar SH. Characterization and regulation of the receptor for insulin-like growth factor I in the FRTL-5 rat thyroid follicular cell lines. Endocrinol 1987; 120: 785-90.